Table 10.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Intestine Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		22	34	23	46	45	68	70	73	79	111
Tx with Antirejection Treatments		17	25	13	32	28	46	24	34	44	40
Antibodies	Category Usage	0.0%	48.0%	30.8%	40.6%	25.0%	17.4%	20.8%	47.1%	47.7%	35.0%
	ALG	0.0%	0.0%	0.0%	9.4%	3.6%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.0%	0.0%	0.0%	0.0%	3.6%	0.0%	0.0%	0.0%	0.0%	2.5%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	0.0%	0.0%	0.0%
	OKT3	0.0%	48.0%	30.8%	34.4%	17.9%	17.4%	12.5%	44.1%	31.8%	32.5%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	11.8%	18.2%	7.5%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	5.9%	4.5%	0.0%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	6.8%	0.0%
Corticosteroids	Category Usage	100.0%	100.0%	100.0%	90.6%	92.9%	93.5%	91.7%	85.3%	75.0%	82.5%
	Steroids	100.0%	100.0%	100.0%	90.6%	92.9%	93.5%	91.7%	85.3%	75.0%	82.5%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.